Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET

Company Participants

Carlo Tanzi - Head of Investor Relations

Eric Shaff - President and Chief Executive Officer

Lisa von Moltke - Chief Medical Officer

Matthew Henn - Chief Scientific Officer

David Arkowitz - Chief Financial Officer

Terri Young - Chief Commercial and Strategy Officer

David Ege - Chief Technology Officer

Conference Call Participants

Mark Breidenbach - Oppenheimer

Peyton Bohnsack - Cowen

John Newman - Canaccord

Chris Howerton - Jeffries

Vernon Bernardino - H.C. Wainwright

Operator

Welcome to Seres Therapeutics First Quarter 2022 Financial Results Conference Call. All participants are in a listen-only mode [Operator Instructions].

I'd now like to turn the conference over to Dr. Carlo Tanzi, Head of Investor Relations. Please go ahead.

Carlo Tanzi

Thank you, Amulet and good morning. Our press release with the company’s first quarter 2022 financial results and a business update became available at 7.00 AM Eastern Time this morning, and can be found on the new Investors and News sections of the company’s Web site. I would like to remind you that, we will be making forward-looking statements, including potential approval of SER-109 and its status as a first-in-class therapeutic, the timing of a BLA filing and potential product launch, market for SER-109, our development opportunities and the ultimate safety and efficacy data for our product. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the Risk Factor section of our recent SEC filings. Any forward-looking statements made on today’s call represent our views as of today only. We may update these statements in the future but we disclaim any obligation to do so.

On today’s call with prepared remarks, I’m joined by Eric Shaff, President and Chief Executive Officer; Dr. Lisa von Moltke, Chief Medical Officer; Dr. Matthew Henn, Chief Scientific Officer; and David Arkowitz, Chief Financial Officer. During the Q&A portion of the call, we will also be joined by Dr. Terri Young, Chief Commercial and Strategy Officer; and Dr. David Ege, Chief Technology Officer. And with that, I’ll pass the call to Eric.

Eric Shaff

Thank you, Carlo and good morning, everyone. We entered 2022 excited about the opportunity for Seres to bring the first microbiome therapeutic to patients. Throughout the first quarter and in recent weeks, Seres continued to make steady progress across our microbiome therapeutics pipeline. At the center of these advances is our SER-109 program, where we expect to complete a BLA filing in the middle of this year in support of a potential commercial launch in the first half of next year. We believe that SER-109 has the potential to become the first ever FDA approved microbiome therapeutic, a landmark for this emerging class of medicines. Having SER-109 FDA approval, we believe we have the opportunity to fundamentally transform the treatment of recurrent C diff infection and potentially provide patients with a far superior treatment option that is available today.